Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors Academic Article uri icon

Overview

MeSH Major

  • Cisplatin
  • Drug Resistance, Neoplasm
  • Neoplasms, Germ Cell and Embryonal

abstract

  • In GCT, TP53 and MDM2 alterations were associated with cisplatin resistance and inferior outcomes, independent of the IGCCCG model. The finding of frequent TP53 alterations among mediastinal primary nonseminomas may explain the more frequent chemoresistance observed with this tumor subtype. A substantial portion of cisplatin-resistant GCTs harbor actionable alterations, which might respond to targeted therapies. Genomic profiling of patients with advanced GCT could improve current risk stratification and identify novel therapeutic approaches for patients with cisplatin-resistant disease.

publication date

  • November 20, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5477828

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.68.7798

PubMed ID

  • 27646943

Additional Document Info

start page

  • 4000

end page

  • 4007

volume

  • 34

number

  • 33